share_log

Vivos Therapeutics | EFFECT: Others

Vivos Therapeutics | EFFECT: Others

Vivos Therapeutics | EFFECT:其他
美股SEC公告 ·  08/08 18:11
牛牛AI助理已提取核心訊息
Vivos Therapeutics, Inc., a company listed in the United States, has achieved a significant milestone with the Securities and Exchange Commission (SEC) declaring its Form S-3 effective as of August 7, 2024, at 4:30 P.M. The Form S-3 is a registration form that allows companies to provide updated financial information and securities offerings to potential investors. This effectiveness indicates that Vivos Therapeutics has met the necessary regulatory requirements to move forward with its securities offerings.
Vivos Therapeutics, Inc., a company listed in the United States, has achieved a significant milestone with the Securities and Exchange Commission (SEC) declaring its Form S-3 effective as of August 7, 2024, at 4:30 P.M. The Form S-3 is a registration form that allows companies to provide updated financial information and securities offerings to potential investors. This effectiveness indicates that Vivos Therapeutics has met the necessary regulatory requirements to move forward with its securities offerings.
在美國上市的vivos therapeutics公司已經實現了重要的里程碑,在2024年8月7日下午4:30,證券交易委員會(SEC)宣佈其提交的S-3表格有效。S-3表格是一種註冊表,允許公司向潛在投資者提供更新的財務信息和證券發行計劃。這一生效表明vivos therapeutics已經滿足了前進證券發行計劃的必要監管要求。
在美國上市的vivos therapeutics公司已經實現了重要的里程碑,在2024年8月7日下午4:30,證券交易委員會(SEC)宣佈其提交的S-3表格有效。S-3表格是一種註冊表,允許公司向潛在投資者提供更新的財務信息和證券發行計劃。這一生效表明vivos therapeutics已經滿足了前進證券發行計劃的必要監管要求。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。